Alterity Therapeutics Secures AU$20 million to Advance ATH434 After Positive Phase 2 Data

Alterity Therapeutics Limited (ASX: ATH) has raised AU$20.0 million via a placement of new shares to Australian and international professional investors. The funds were secured at AU$0.012 per share, reflecting a 7.7% discount to the last ASX close, and no options were issued. Backed by a leading healthcare-focused fund, the placement strengthens Alterity’s balance sheet and institutional register, while providing capital to advance its clinical and regulatory programs for ATH434, a disease-modifying therapy for Multiple System Atrophy (MSA) .  Proceeds will support non-clinical studies, chemical manufacturing and controls (CMC), clinical development, and regulatory activities with the US FDA and other agencies. Earlier this year, Alterity reported positive Phase 2 trial results for ATH434, demonstrating both efficacy and safety in MSA patients. CEO David Stamler stated the raise positions the company well to pursue strategic partnerships and progress toward future approval.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com